Piper Jaffray on Sarepta Therapeutics' (SRPT +0.4%) eteplirsen update: The long-term benefits should support accelerated FDA approval. The shares are reiterated at Overweight, price target $50. Meanwhile, SA contributor Carl Cachia weighs in, calling the company's potential "massive," while TheStreet's Adam Feuerstein also seems impressed. Another SA contributor, Cory Renauer wonders if the young men involved in the trials "realize how important their six-minute walks and muscle biopsies are to the near term future of DMD patients in the US, and SRPT's investors."
From other sites
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs